Compare Amphastar Pharmaceuticals Inc (AMPH) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Upstart Holdings Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Upstart Holdings Inc trades at $29.91 (market cap $2.94B). The key difference: Upstart Holdings Inc is far larger — about 3.4× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | UPST | |
|---|---|---|
Market Cap | $863.95M | $2.94B |
Sector | Health | Financials |
52-Week High | $30.81 | $73.76 |
52-Week Low | $16.87 | $24.22 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Upstart (UPST) trades at $31.09, up 4.64% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth of 42% year-over-year and a return to GAAP profitability, with loan originations surging 50%. However, it has missed EPS expectations for three consecutive quarters. The stock is supported by a consensus analyst price target of $47.20, implying significant upside, but faces headwinds from high interest rates and competitive pressures.
The outlook is mixed: strong loan growth and AI-driven underwriting improvements offer growth potential, but recent earnings misses, a high P/E ratio of 59.79, and negative operating cash flow in 2025 pose risks. Investor sentiment is cautiously optimistic, with 45% of analysts rating it a Buy, though volatility from macroeconomic factors remains a key concern for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
